Payment overview · 2025
General Payments
$610.99
25 reported records · 12 companies
Healthcare provider profile · identity verified
Robert A Crossey, DO
Allopathic & Osteopathic Physicians|Family Medicine · IRWIN, PA · NPI 1689617912
Verified facts
What the public records show
CMS Open Payments records show Robert A Crossey, DO received $610.99 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.41 | 27.2% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $124.79 | 20.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $76.20 | 12.5% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.93 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.60 | 5.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.47 | 5.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.46 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.08 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.02 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.98 | 3.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.81 | 3.1% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.24 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $610.99 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $124.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $76.20 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.84 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.84 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1272 | 300 |
| Levothyroxine Sodium | Levothyroxine Sodium | 939 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 693 | 146 |
| Lisinopril | Lisinopril | 579 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 544 | 126 |
| Gabapentin | Gabapentin | 532 | 83 |
| Omeprazole | Omeprazole | 488 | 119 |
| Simvastatin | Simvastatin | 423 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 100 |
| Furosemide | Furosemide | 387 | 76 |
| Famotidine | Famotidine | 382 | 80 |
| Trazodone Hcl | Trazodone Hcl | 380 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 375 | 91 |
| Losartan Potassium | Losartan Potassium | 370 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 366 | 89 |
| Metformin Hcl | Metformin Hcl | 357 | 101 |
| Sertraline Hcl | Sertraline Hcl | 347 | 60 |
| Eliquis | Apixaban | 315 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 289 | 50 |
| Potassium Chloride | Potassium Chloride | 273 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 75 |
| Quetiapine Fumarate | Quetiapine Fumarate | 260 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 49 |
| Warfarin Sodium | Warfarin Sodium | 234 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 47 |
| Donepezil Hcl | Donepezil Hcl | 227 | 40 |
| Alprazolam | Alprazolam | 203 | 57 |
| Meloxicam | Meloxicam | 202 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 47 |
| Mirtazapine | Mirtazapine | 181 | 30 |
| Buspirone Hcl | Buspirone Hcl | 178 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 160 | 115 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 24 |
| Prednisone | Prednisone | 135 | 56 |
| Bumetanide | Bumetanide | 134 | 22 |
| Ozempic | Semaglutide | 134 | 21 |
| Carvedilol | Carvedilol | 132 | 30 |
| Montelukast Sodium | Montelukast Sodium | 131 | 23 |
| Lorazepam | Lorazepam | 130 | 30 |
| Ezetimibe | Ezetimibe | 126 | 31 |
| Allopurinol | Allopurinol | 124 | 31 |
| Chlorthalidone | Chlorthalidone | 119 | 28 |
| Levetiracetam | Levetiracetam | 118 | 16 |
| Xarelto | Rivaroxaban | 118 | 19 |
| Finasteride | Finasteride | 117 | 30 |
| Metformin Hcl Er | Metformin Hcl | 114 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 41 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 105 | 15 |
| Glimepiride | Glimepiride | 102 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 48 |
| Atenolol | Atenolol | 94 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 17 |
| Synthroid | Levothyroxine Sodium | 93 | 18 |
| Tramadol Hcl | Tramadol Hcl | 91 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 28 |
| Celecoxib | Celecoxib | 83 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 80 | 19 |
| Memantine Hcl | Memantine Hcl | 80 | 17 |
| Pregabalin | Pregabalin | 80 | 16 |
| Ibuprofen | Ibuprofen | 78 | 29 |
| Baclofen | Baclofen | 75 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 15 |
| Clonazepam | Clonazepam | 72 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 59 |
| Jardiance | Empagliflozin | 66 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 18 |
| Methylprednisolone | Methylprednisolone | 65 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 18 |
| Spironolactone | Spironolactone | 63 | 15 |
| Primidone | Primidone | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 12 |
| Aripiprazole | Aripiprazole | 60 | suppressed |
| Valsartan | Valsartan | 60 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 14 |
| Digoxin | Digoxin | 56 | 12 |
| Glipizide | Glipizide | 54 | 13 |
| Latanoprost | Latanoprost | 54 | 12 |
| Olanzapine | Olanzapine | 54 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 16 |
| Meclizine Hcl | Meclizine Hcl | 46 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 29 |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Midodrine Hcl | Midodrine Hcl | 44 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Naproxen | Naproxen | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Carbamazepine Er | Carbamazepine | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Loperamide | Loperamide Hcl | 36 | 16 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Nystatin | Nystatin | 33 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Budesonide | Budesonide | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 13 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Trospium Chloride | Trospium Chloride | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 17 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ibu | Ibuprofen | 20 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Nystop | Nystatin | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $610.99 · 25 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, GARDASIL 9, INSPIRE, KISUNLA, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, YUPELRI, ZAVZPRET, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error